BioLineRX
BLRX
28 hedge funds and large institutions have $40.9M invested in BioLineRX in 2017 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 7 increasing their positions, 7 reducing their positions, and 4 closing their positions.
0% more funds holding
Funds holding: 28 → 28 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% less ownership
Funds ownership: 0.06% → 0.06% (-0%)
0% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 4
0% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 7
6% less capital invested
Capital invested by funds: $43.4M → $40.9M (-$2.45M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$181K |
| 2 |
Morgan Stanley
New York
|
+$153K |
| 3 |
Millennium Management
New York
|
+$95.5K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$46.8K |
| 5 |
JP Morgan Chase
New York
|
+$31.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$1.7M |
| 2 |
MCC
Malaga Cove Capital
Pv Estates,
California
|
-$51K |
| 3 |
HIIFS
Harel Insurance Investments & Financial Services
Ramat Gan,
Israel
|
-$47.4K |
| 4 |
Bank of New York Mellon
New York
|
-$20K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$18K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
FMA
26
FNY Managed Accounts
New York
| $2K | -$15.2K | -23 | -85% |
|
27
Royal Bank of Canada
Toronto,
Ontario, Canada
| $1K | -$1.98K | -3 | -60% |
|
|
KF
28
Krilogy Financial
St. Louis,
Missouri
| $1K | – | – | – |
|
|
RE
29
RBC Europe
London,
United Kingdom
| $218 | – | – | – |
|
|
MCC
30
Malaga Cove Capital
Pv Estates,
California
| – | -$51K | -73 | Closed |
|
|
31
Bank of New York Mellon
New York
| – | -$20K | -30 | Closed |
|
|
32
Bank of America
Charlotte,
North Carolina
| – | -$18K | -27 | Closed |
|
33
Wells Fargo
San Francisco,
California
| – | -$1K | -2 | Closed |
|
BLRX Hedge Fund Activity: Q4 2017 in Review
28 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in BioLineRX (BLRX) for Q4 2017, worth a combined $40.9M — down 5.6% from $43.4M a quarter earlier.
Fund positioning in BLRX was balanced in Q4 2017: 4 funds opened new positions, 4 closed out, 7 added to existing stakes and 7 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $181K. The largest seller was Deutsche Bank, cutting an estimated $1.7M.
- 28 institutional investors held BioLineRX (BLRX) as of Q4 2017, unchanged from Q3 2017.
- Funds reported $40.9M of BioLineRX stock for Q4 2017, down 5.6% quarter-over-quarter.
- 4 funds opened new BioLineRX positions in Q4 2017 and 4 closed out, a net change of 0 holders.
- The largest BioLineRX buyer in Q4 2017 was Renaissance Technologies, an estimated $181K added.
- The largest BioLineRX seller in Q4 2017 was Deutsche Bank, an estimated $1.7M sold.
Based on aggregated 13F filings for Q4 2017.